Localize and Controlled co-delivery of AuNPs conjugated siRNA by Cationic Shear-...
Localize and Controlled co-delivery of AuNPs conjugated siRNA by Cationic Shear-thinning Gel Matrix for Treatment of Arthritis (DesiRTA)
Arthritis is a common metabolic and immune associate disease that causes chronic pain and inflammation in a joint. Approximately
312 million people are affected by arthritis globally. It affects adults of all ages, both sexes, and...
ver más
¿Tienes un proyecto y buscas un partner? Gracias a nuestro motor inteligente podemos recomendarte los mejores socios y ponerte en contacto con ellos. Te lo explicamos en este video
Proyectos interesantes
IA-NANO
Albumin particles for intra articular delivery of celecoxib...
197K€
Cerrado
SINPAIN
A game changer for the treatment of osteoarthritis: a cost e...
5M€
Cerrado
grabRNA
Smart RNA delivery for therapy and diagnostic
150K€
Cerrado
TraffikGene-Tx
TraffikGene-Tx: Targeted Peptide Carriers for RNA Delivery
2M€
Cerrado
CTQ2016-75363-R
DESARROLLO DE ESTRATEGIAS Y AGENTES TERAPEUTICOS INNOVADORES
105K€
Cerrado
Duración del proyecto: 36 meses
Fecha Inicio: 2023-03-30
Fecha Fin: 2026-03-31
Líder del proyecto
UNIVERSITY OF LIMERICK
No se ha especificado una descripción o un objeto social para esta compañía.
TRL
4-5
Presupuesto del proyecto
200K€
Fecha límite de participación
Sin fecha límite de participación.
Descripción del proyecto
Arthritis is a common metabolic and immune associate disease that causes chronic pain and inflammation in a joint. Approximately
312 million people are affected by arthritis globally. It affects adults of all ages, both sexes, and all races and ethnicities, but the
prevalence in women is more than in men. Professional organizations have established many arthritis treatment regimens and
management guidelines; in those nonsteroidal anti-inflammatory drugs (NSAIDs), steroids and biologicals are the main ones. These are
effective against the disease aggressiveness and pain up to some extent, but the problem is this treatment is only symptomatic and
requires taking them lifelong; in that case, these drugs cause severe health problems and again increase the economic burden. For
these reasons, we need to develop a therapeutic technique and medication that can eliminate the symptom and causes of the disease
forever and prevent the ever-increasing number of patients worldwide. DesiTRA projects are an effort in the same vein to develop an
effective therapeutic alternative for arthritis that will avoid the aggravation of disease symptoms and cause of the disease together,
without causing any health-associated side effects. In this, mainly gold nanoparticle (AuNPs) conjugated siRNA will be delivered at the
disease site locally. Modified polysaccharides will increase the stability and release rate of AuNPs-siRNA, and these assemblies will be
delivered very controlled and precisely through a synovial fluid mimicking the shear-thinning hydrogel system. The ambitious
project will be conducted at two different groups and laboratories in Ireland and Portugal. The project involves experienced
researchers of other but related areas that will allow applicants to work in multidisciplinary aspects. The prestigious fellowship will
provide a plate form of renowned subject experts, and exposure to international collaborators will provide a unique opportunity to
grow as a true researcher